ShRNA-mediated knock-down of CD200 using the self-assembled nanoparticle-forming derivative of polyethylenimine

Document Type : Research Paper


1 Department of Pharmaceutical Biotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran

2 Medicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran

3 Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran


Objective(s): ShRNA-mediated silencing strategy is considered to be a potent therapeutic approach. The present study aimed to assess the ability of the previously prepared polyethylenimine (PEI) derivative for the shRNA knock-down of the CD200 gene on the cells obtained from the patients with chronic lymphocytic leukemia (CLL).
Materials and Methods: Since there are several investigations regarding the role of CD200 over-expression in the progression of several malignancies (e.g., CLL), polyplexes were prepared using succinylated PEI and the plasmid encoding anti-CD200 shRNA. The ability of the nanoparticles for CD200 silencing at the levels of protein and mRNA, as well as the apoptotic effects induced by unmodified PEI and its derivative, were evaluated.
Results: Conjugation of succinic acid using the primary amines of PEI reduced the cell-induced toxicity of the polymer. Under such circumstances, 92.1% of the cells remained alive after treatment with the nanoparticles based on modified PEI. In addition, CD200 knock-down evaluations demonstrated a 50% reduction in the expression of the gene in the samples obtained from patients with CLL, while using the same formulation on the cells obtained from healthy donors decreased the CD200+ cells up to 10%. The results of CD200 silencing at the mRNA level revealed that the shRNA formulation could reduce the CD200 level in the cells of the patients by 3.2-6.06-fold relative to the cells transfected with non-effective, scrambled shRNA.
Conclusion: Our findings supported the application of succinylated PEI for the down-regulation of the CD200 gene in the upcoming attempts to develop nano-carriers for gene therapy.


1.Makkouk A, Weiner GJ. Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge. Cancer Res. 2015; 75(1): 5-10.
2.Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015; 348( 6230): 69-74.
3.Fan Y, Moon J. Nanoparticle drug delivery systems designed to improve cancer vaccines and immunotherapy. Vaccines. 2015; 3(3): 662-685.
4.Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, Meng M, Fritz D, Vascotto F, Hefesha H. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016; 534(7607): 396.
5.Kretz Rommel A, Qin F, Dakappagari N, Ravey EP, McWhirter J, Oltean D, Frederickson S, Maruyama T, Wild MA, Nolan MJ. CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy. J Immunol. 2007; 178(9): 5595-5605.
6.Liao KL, Bai XF, Friedman A. The role of CD200–CD200R in tumor immune evasion. J Theor Biol. 2013; 328: 65-76.
7.Barclay AN, Wright GJ, Brooke G, Brown MH. CD200 and membrane protein interactions in the control of myeloid cells. Trends Immunol. 2002; 23(6): 285-290.
8.Moreaux J, Hose D, Reme T, Jourdan E, Hundemer M, Legouffe E, Moine P, Bourin P, Moos M, Corre J. CD200 is a new prognostic factor in multiple myeloma. Blood. 2006; 108(13): 4194-4197.
9.Tonks A, Hills R, White P, Rosie B, Mills KI, Burnett AK, Darley RL. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia. 2007; 21(3): 566.
10.Wong KK, Khatri I, Shaha, S, Spaner DE, Gorczynski RM. The role of CD200 in immunity to B cell lymphoma. J Leukocyte Biol. 2010; 88(2): 361-372.
11.Knauf WU, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Herbrecht R, Juliusson G, Postner G, Gercheva L, Goranov S. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009; 27(26): 4378-4384.
12.Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC. The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood. 2010; 116(19): 3705-3714.
13.Mahadevan D, Lanasa MC, Whelden M, Faas SJ, Ulery TL, Kukreja A, Li L, Bedrosian CL, Heffner LT. First-in-human phase I dose escalation study of a humanized anti-CD200 antibody (Samalizumab) in patients with advanced stage B cell chronic lymphocytic leukemia (B-CLL) or multiple myeloma (MM). Blood. 2010; 116:2465.
14.Kim DH, Rossi JJ. Overview of gene silencing by RNA interference. Curr Protoc Nucleic Acid Chem. 2009; 36(1): 1-10.
15.Rao DD, Vorhies JS, Senzer N, Nemunaitis J. siRNA vs. shRNA: similarities and differences. Adv Drug Delivery Rev. 2009; 61(9): 746-759.
16.Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2012–an update. J Gene Med. 2013; 15(2): 65-77.
17.Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014; 15(8):541-555.
18.Pandey AP, Sawant KK. Polyethylenimine: A versatile, multifunctional non-viral vector for nucleic acid delivery. Mater Sci Eng C. 2016; 68: 904-918.
19.Boussif O, Lezoualc’h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, Behr JP. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA. 1995; 92(16): 7297-7301.
20.Nouri F, Sadeghpour H, Heidari R, Dehshahri A., Preparation, characterization, and transfection efficiency of low molecular weight polyethylenimine-based nanoparticles for delivery of the plasmid encoding CD200 gene. Int J Nanomed. 2017; 12: 5557-5569.
21.Benjaminsen RV, Mattebjerg MA, Henriksen JR, Moghimi SM, AndresenTL. The possible “proton sponge” effect of polyethylenimine (PEI) does not include change in lysosomal pH. Mol Ther. 2013; 21(1): 149-157.
22.Dehshahri A, Oskuee RK, Ramezani M. Plasmid DNA delivery into hepatocytes using a multifunctional nanocarrier based on sugar-conjugated polyethylenimine. Gene Ther Mol Biol. 2012; 14: 62-71.
23.Dehshahri A, Alhashemi SH, Jamshidzadeh A, Sabahi Z, Samani SM, Sadeghpour H, Mohazabieh E, Fadaei M. Comparison of the effectiveness of polyethylenimine, polyamidoamine and chitosan in transferring plasmid encoding interleukin-12 gene into hepatocytes. Macromol Res. 2013; 21(12): 1322-1330.
24.Oskuee RK, Dehshahri A, Shier T, Ramezani M. Modified polyethylenimine: Self assemble nanoparticle forming polymer for pDNA delivery. Iran J Basic Med Sci. 2008; 11(1): 33-40.
25.Dehshahri A, Sadeghpour H, Oskuee RK, Fadaei M, Sabahi Z, Alhashemi SH, Mohazabieh E. Interleukin-12 plasmid DNA delivery using l-thyroxine-conjugated polyethylenimine nanocarriers. J Nanopart Res. 2014; 16(5): 1-14.
26.Khalvati B, Sheikhsaran F, Sharifzadeh S, Kalantari T, Behzad Behbahani A, Jamshidzadeh A, Dehshahri A. Delivery of plasmid encoding interleukin-12 gene into hepatocytes by conjugated polyethylenimine-based nanoparticles. Artif Cells Nanomed Biotechnol. 2017; 45(5): 1036-1044.
27.Dehshahri A, Sadeghpour H, Keykhaee M, Khalvati B, Sheikhsaran F. Enhanced delivery of plasmid encoding interleukin-12 gene by diethylene triamine penta-acetic acid (DTPA)-conjugated PEI nanoparticles. Appl Biochem Biotechnol. 2016; 179(2): 251-269.
28.Sheikhsaran F, Sadeghpour H, Khalvati B, Entezar-Almahdi E, Dehshahri A. Tetraiodothyroacetic acid-conjugated polyethylenimine for integrin receptor mediated delivery of the plasmid encoding IL-12 gene. Colloids Surf B Biointerfaces. 2017; 150: 426-436.
29.Sadeghpour H, Nasrabad, KR, Haghighi MA, Dehshahri A. Preparation and characterization of celecoxib-conjugated polyethylenimine as a potential nanocarrier for gene delivery. Trends Pharm Sci. 2018; 4: 17-28
30.Sadeghpour H, Khalvati B, Entezar-Almahdi E, Savadi N, Alhashemi SH, Raoufi M, Dehshahri A. Double domain polyethylenimine-based nanoparticles for integrin receptor mediated delivery of plasmid DNA. Sci Rep. 2018; 8(1): 1-12.
31.Zintchenko A, Philipp A, Dehshahri A, Wagner E. Simple modifications of branched PEI lead to highly efficient siRNA carriers with low toxicity. Bioconjug Chem. 2008; 19(7): 1448-1455.
32.Shi B, Zheng M, Tao W, Chung R, Jin D, Ghaffari D, Farokhzad OC. Challenges in DNA delivery and recent advances in multifunctional polymeric DNA delivery systems. Biomacromolecules. 2017; 18(8): 2231-2246.
33.Hall A, Lächelt U, Bartek J, Wagner E, Moghimi SM. Polyplex evolution: understanding biology, optimizing performance. Mol Ther. 2017; 25(7): 1476-1490.
34.Teo PY, Yang C, Hedrick JL, Engler AC, Coady DJ, Ghaem-Maghami S, George AJ, Yang YY. Hydrophobic modification of low molecular weight polyethylenimine for improved gene transfection. Biomaterials. 2013; 34(32): 7971-7979.
35.Dehshahri A, Oskuee RK, Shier WT, Hatefi A, Ramezani M. Gene transfer efficiency of high primary amine content, hydrophobic, alkyl-oligoamine derivatives of polyethylenimine. Biomaterials. 2009; 30(25): 4187-4194.
36.Thomas M, Ge Q, Lu JJ, Chen J, Klibanov A. Cross-linked small polyethylenimines: while still nontoxic, deliver DNA efficiently to mammalian cells in vitro and in vivo. Pharm Res. 2005; 22(3): 373-380.
37.Elfinger M, Uzgun S, Rudolph C. Nanocarriers for gene delivery-polymer structure, targeting ligands and controlled-release devices. Curr Nanosci. 2008; 4(4): 322-353.
38.Parhamifar L, Larsen AK, Hunter AC, Andresen TL, Moghimi SM. Polycation cytotoxicity: a delicate matter for nucleic acid therapy—focus on polyethylenimine. Soft Matter. 2010: 6(17): 4001-4009.
39.Moghimi SM, Symonds P, Murray JC, Hunter AC, Debska G, Szewczyk A. A two-stage poly (ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy. Mol Ther. 2005; 11(6): 990-995.
40.Gabrielson NP, Pack DW. Acetylation of polyethylenimine enhances gene delivery via weakened polymer/DNA interactions. Biomacromolecules. 2006; 7(8): 2427-2435.